

Paolo Corradini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6791150/publications.pdf>

Version: 2024-02-01

314
papers

19,419
citations

9234

74
h-index

14156

128
g-index

323
all docs

323
docs citations

323
times ranked

13899
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e426-e438.	2.9	23
2	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. <i>Haematologica</i> , 2022, 107, 1153-1162.	1.7	15
3	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
4	T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. <i>British Journal of Haematology</i> , 2022, 196, 548-558.	1.2	73
5	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	2.5	46
6	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	0.6	70
7	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	2.5	16
8	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	2.0	32
9	Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3834.	1.8	0
10	Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. <i>British Journal of Haematology</i> , 2022, 198, 82-92.	1.2	12
11	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	2.5	8
12	Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects <i>In Vivo</i> Expansion and Disease Response in Patients with Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 3378-3386.	3.2	15
13	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3131.	0.8	29
14	A three-gene signature based on MYC, BCL-2, and NFKB1A improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.	1.7	8
15	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 655-663.	1.3	7
16	Total body irradiation + fludarabine compared to busulfan + fludarabine as reduced-toxicity conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	1.3	10
17	A brief rituximab, bendamustine, mitoxantrone (R ² EBM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4
18	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45

#	ARTICLE	IF	CITATIONS
19	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
20	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 328.e1-328.e6.	0.6	2
21	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	0.6	40
22	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. <i>HemaSphere</i> , 2021, 5, e612.	1.2	29
23	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
24	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
25	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6479-6490.	3.2	9
26	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021, 106, 2578-2587.	1.7	15
27	<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). <i>Haematologica</i> , 2021, 106, 2918-2926.	1.7	18
28	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
29	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5
30	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	1.7	29
31	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 509-518.	0.2	91
32	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 884-890.	1.3	13
33	Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. <i>British Journal of Haematology</i> , 2020, 188, 907-917.	1.2	8
34	Selective inhibitors of nuclear export in aggressive B-cell lymphomas. <i>Lancet Haematology</i> , 2020, 7, e500-e501.	2.2	1
35	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , 2020, 7, e861-e873.	2.2	34
36	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020, 20, 1140.	1.1	12

#	ARTICLE	IF	CITATIONS
37	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET- ¹⁸ F-adapted HD0607 trial. <i>Cancer Medicine</i> , 2020, 9, 8735-8746.	1.3	10
38	Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e256-e262.	2.0	4
39	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
40	Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e402.	1.2	15
41	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). <i>Cancers</i> , 2020, 12, 2242.	1.7	5
42	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	6.9	32
43	Handling the COVID-19 pandemic in the oncological setting. <i>Lancet Haematology</i> , 2020, 7, e365-e366.	2.2	12
44	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). <i>Bone Marrow Transplantation</i> , 2020, 55, 2077-2086.	1.3	5
45	Early serum ¹⁸ F-TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. <i>Hematological Oncology</i> , 2020, 38, 501-508.	0.8	8
46	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1917.	5.8	99
47	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 830-844.	2.5	54
48	Allogeneic Transplantation for Relapsed Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 365-380.	0.2	0
49	Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
50	Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi. <i>Blood</i> , 2020, 136, 21-21.	0.6	1
51	Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment. <i>Leukemia and Lymphoma</i> , 2019, 60, 477-482.	0.6	7
52	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. <i>Nature Communications</i> , 2019, 10, 3835.	5.8	183
53	Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma. <i>British Journal of Cancer</i> , 2019, 121, 567-577.	2.9	6
54	INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLEUCCEL IN THE JULIET TRIAL. <i>Hematological Oncology</i> , 2019, 37, 505-507.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. <i>Haematologica</i> , 2019, 104, 2241-2248.	1.7	13
56	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 628-634.	2.0	16
57	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
58	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019, 3, 1103-1117.	2.5	23
59	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
60	CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLEUCCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. <i>Hematological Oncology</i> , 2019, 37, 308-310.	0.8	4
61	CAR T-cells: Driving in the Fast Lane. <i>HemaSphere</i> , 2019, 3, e209.	1.2	1
62	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019, 3, e284.	1.2	9
63	First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. <i>Blood Cancer Journal</i> , 2019, 9, 100.	2.8	33
64	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1237-1244.	1.3	5
65	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 1047-1051.	3.3	27
66	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	2.0	15
67	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , 2019, 51, 419-424.	0.4	9
68	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1204-1213.	0.6	4
69	Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. <i>Leukemia and Lymphoma</i> , 2019, 60, 101-109.	0.6	7
70	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018, 181, 86-96.	1.2	23
71	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	1.2	8
72	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 255-263.	1.3	14

#	ARTICLE	IF	CITATIONS
73	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018, 32, 979-985.	3.3	25
74	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018, 53, 461-473.	1.3	28
75	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1522-1531.	1.3	22
76	Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 406-409.	2.0	16
77	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. <i>Leukemia</i> , 2018, 32, 1043-1047.	3.3	87
78	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	1.7	225
79	Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 859-870.	1.2	45
80	Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. <i>Annals of Hematology</i> , 2018, 97, 1301-1315.	0.8	6
81	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.	3.3	137
82	T-Cell Lymphomas. , 2018, , 1343-1380.		1
83	Genomic patterns of progression in smoldering multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3363.	5.8	163
84	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.2	9
85	Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 2902-2902.	0.6	3
86	Carfilzomib, bendamustine, and dexamethasone (Kbd) in advanced multiple myeloma: The EMN09-trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 8019-8019.	0.8	8
87	Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. <i>Blood</i> , 2018, 132, 4115-4115.	0.6	0
88	Bronchial fibroepithelial polyp: a clinico-radiologic, bronchoscopic, histopathological and <i>in situ</i> hybridisation study of 15 cases of a poorly recognised lesion. <i>Clinical Respiratory Journal</i> , 2017, 11, 43-48.	0.6	11
89	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. <i>Expert Review of Hematology</i> , 2017, 10, 479-492.	1.0	34
90	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1549-1554.	2.0	25
92	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 821-836.	1.4	4
93	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
94	Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. <i>Cancer</i> , 2017, 123, 3701-3708.	2.0	12
95	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	1.3	53
96	Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. <i>Leukemia Research</i> , 2017, 62, 91-97.	0.4	16
97	Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients. <i>Bone Marrow Transplantation</i> , 2017, 52, 1602-1608.	1.3	13
98	ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT-VERSUS-HOST DISEASE FREE/RELAPSE-FREE SURVIVAL (GRFS). <i>Hematological Oncology</i> , 2017, 35, 169-190.	0.8	0
99	FIL-PTCL13: PHASE IB/II STUDY OF ROMIDEPSIN/CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS.. <i>Hematological Oncology</i> , 2017, 35, 426-426.	0.8	0
100	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	1.7	11
101	Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogeneic hematopoietic stem cell transplantation for hematological malignancies: two case reports. <i>Haematologica</i> , 2017, 102, e423-e426.	1.7	7
102	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3425-3432.	0.8	132
103	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	0.8	21
104	THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, e2016045.	0.5	4
105	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. <i>European Journal of Haematology</i> , 2016, 97, 554-561.	1.1	9
106	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. <i>Transplantation</i> , 2016, 100, e147-e155.	0.5	40
107	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 38.	6.9	34
108	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. <i>Leukemia</i> , 2016, 30, 2086-2089.	3.3	45

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	0.6	144
110	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 4015-4022.	0.8	66
111	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. <i>Blood Cancer Journal</i> , 2016, 6, e491-e491.	2.8	4
112	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Annals of Oncology</i> , 2016, 27, 2251-2257.	0.6	40
113	Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2016, 44, 624-634.e1.	0.2	26
114	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	0.6	5
115	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 783-791.	0.4	35
116	Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. <i>Blood</i> , 2016, 128, 3334-3334.	0.6	5
117	Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2015, 22, 469-475.	1.2	0
118	Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects. <i>Clinical Cancer Research</i> , 2015, 21, 3740-3749.	3.2	110
119	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 507-513.	0.2	13
120	An uncommon cause of weaning failure from mechanical ventilation. <i>Intensive Care Medicine</i> , 2015, 41, 327-328.	3.9	0
121	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	1.3	16
122	The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1068-1073.	2.0	46
123	Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. <i>Oncologist</i> , 2015, 20, 323-328.	1.9	29
124	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 404-408.	0.2	18
125	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. <i>Blood</i> , 2015, 125, 2855-2864.	0.6	132
126	Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. <i>European Journal of Haematology</i> , 2015, 94, 12-22.	1.1	18

#	ARTICLE	IF	CITATIONS
127	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	5.1	143
128	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	0.8	138
129	Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v108-v115.	0.6	172
130	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1617-1629.	5.1	289
131	Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1969-1974.	0.6	3
132	The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. <i>Leukemia</i> , 2015, 29, 464-473.	3.3	64
133	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. <i>Blood</i> , 2015, 126, 3937-3937.	0.6	1
134	Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. <i>Leukemia and Lymphoma</i> , 2014, 55, 331-336.	0.6	25
135	Plerixafor "on demand": results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. <i>Bone Marrow Transplantation</i> , 2014, 49, 453-455.	1.3	8
136	Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. <i>Leukemia and Lymphoma</i> , 2014, 55, 2032-2037.	0.6	22
137	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. <i>Clinical Cancer Research</i> , 2014, 20, 5641-5651.	3.2	31
138	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2014, 166, 140-142.	1.2	31
139	SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. <i>Annals of Oncology</i> , 2014, 25, 2339-2350.	0.6	15
140	Experts' considerations on HLA haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 187-197.	1.1	24
141	Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lincatuzumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 258-265.	1.2	65
142	Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2049-2055.	2.0	60
143	Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1982-1988.	2.0	14
144	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. <i>Leukemia</i> , 2014, 28, 1885-1891.	3.3	83

#	ARTICLE	IF	CITATIONS
145	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	13.9	683
146	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	5.1	695
147	Autologous Stem Cell Transplantation for T-Cell Lymphomas. <i>Seminars in Hematology</i> , 2014, 51, 59-66.	1.8	16
148	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 885-890.	2.0	42
149	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2014, 99, e14-e16.	1.7	42
150	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014, 124, 3841-3849.	0.6	185
151	Molecular Methods for Detection of Minimal Residual Disease Following Transplantation in Lymphoid and Plasma Cell Disorders. <i>Methods in Molecular Biology</i> , 2014, 1109, 209-237.	0.4	3
152	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
153	Current state of art for transplantation paradigms in peripheral T-cell lymphomas. <i>Expert Review of Hematology</i> , 2013, 6, 465-474.	1.0	3
154	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
155	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 424-428.	2.0	24
156	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 940-948.	2.0	20
157	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2013, 160, 649-659.	1.2	111
158	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
159	Successful second autologous engraftment after long duration storage of hematopoietic stem cells. <i>Bone Marrow Transplantation</i> , 2013, 48, 1480-1481.	1.3	2
160	Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 340-344.	1.1	2
161	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , 2013, 27, 2086-2091.	3.3	37
162	Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. <i>Blood</i> , 2013, 122, 2799-2806.	0.6	80

#	ARTICLE	IF	CITATIONS
163	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013, 121, 5055-5063.	0.6	171
164	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. <i>Blood</i> , 2013, 122, 1376-1383.	0.6	74
165	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. <i>Blood</i> , 2013, 122, 4111-4118.	0.6	90
166	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. <i>Haematologica</i> , 2013, 98, 1014-1021.	1.7	98
167	High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect. <i>Blood</i> , 2013, 122, 2059-2059.	0.6	2
168	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas. , 2013, , 229-242.		0
169	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	3.3	14
170	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. <i>Leukemia</i> , 2012, 26, 520-526.	3.3	129
171	Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia. <i>Leukemia Supplements</i> , 2012, 1, S33-S34.	0.1	0
172	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	0.6	260
173	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 789-795.	0.6	13
174	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 617-626.	2.0	75
175	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	0.8	28
176	Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. <i>European Journal of Haematology</i> , 2012, 89, 111-119.	1.1	16
177	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 108-119.	1.2	36
178	Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. <i>American Journal of Hematology</i> , 2012, 87, 150-154.	2.0	8
179	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).. <i>Journal of Clinical Oncology</i> , 2012, 30, e18572-e18572.	0.8	5
180	Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1262-1270.	0.6	11

#	ARTICLE	IF	CITATIONS
181	Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. <i>European Journal of Cancer</i> , 2011, 47, 814-818.	1.3	16
182	Allogeneic transplantation for Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2011, 152, 261-272.	1.2	22
183	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. <i>Annals of Oncology</i> , 2011, 22, 1614-1621.	0.6	42
184	Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. <i>Toxicology</i> , 2011, 283, 18-23.	2.0	12
185	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2011, 29, 3016-3022.	0.8	171
186	Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 814-824.	0.8	151
187	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2011, 96, 937-942.	1.7	62
188	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1. <i>Blood</i> , 2011, 118, 3976-3976.	0.6	12
189	Allogeneic transplantation for lymphoma: long-term outcome. <i>Current Opinion in Hematology</i> , 2010, 17, 522-530.	1.2	8
190	Pretransplantation [¹⁸ F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. <i>Cancer</i> , 2010, 116, 5001-5011.	2.0	36
191	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. <i>Bone Marrow Transplantation</i> , 2010, 45, 505-512.	1.3	14
192	Immune reconstitution inflammatory syndrome associated with <i>Aspergillus terreus</i> pulmonary infection in an autologous stem cell transplant recipient. <i>Transplant Infectious Disease</i> , 2010, 12, 64-68.	0.7	13
193	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 800-807.	0.8	166
194	High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 2227-2232.	0.8	131
195	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010, 115, 3671-3677.	0.6	151
196	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet</i> , 2010, 376, 2075-2085.	6.3	770
197	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	1.1	21
198	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. <i>Experimental Hematology</i> , 2009, 37, 791-798.	0.2	90

#	ARTICLE	IF	CITATIONS
199	The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1131-1138.	3.3	111
200	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. <i>Bone Marrow Transplantation</i> , 2009, 44, 237-242.	1.3	18
201	Advances in mobilization for the optimization of autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1412-1421.	0.6	48
202	Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. <i>Haematologica</i> , 2009, 94, 654-662.	1.7	62
203	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. <i>Blood</i> , 2009, 113, 4771-4779.	0.6	69
204	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009, 113, 3375-3382.	0.6	92
205	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2009, 114, 5264-5270.	0.6	366
206	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2008, 49, 2156-2162.	0.6	143
207	Eosinophilic Globules in Bronchoalveolar Lavage Fluid of Patients With Systemic Sclerosis-Related Interstitial Lung Disease. <i>American Journal of Clinical Pathology</i> , 2008, 130, 927-933.	0.4	1
208	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. <i>Journal of Clinical Oncology</i> , 2008, 26, 3166-3175.	0.8	68
209	Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 254-255.	4.3	0
210	Prospective, multicenter randomized GITMO/IIIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008, 111, 4004-4013.	0.6	243
211	Traumatic Neuroma of the Bronchi: Bronchoscopy and Histology of a Hitherto Unreported Lesion. <i>American Journal of Surgical Pathology</i> , 2008, 32, 640-641.	2.1	9
212	The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations .. <i>Blood</i> , 2008, 112, 2144-2144.	0.6	2
213	Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorothamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2008, 112, 2586-2586.	0.6	5
214	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 3303-3303.	0.6	26
215	RIC Allogeneic Transplantation Improves the Overall and Progression-Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLA Typing and Donor Availability. <i>Blood</i> , 2008, 112, 460-460.	0.6	0
216	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. <i>Journal of Clinical Oncology</i> , 2007, 25, 4459-4465.	0.8	301

#	ARTICLE	IF	CITATIONS
217	Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2007, 48, 759-766.	0.6	27
218	Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2007, 48, 1496-1501.	0.6	14
219	IFN- γ Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. <i>Cancer Research</i> , 2007, 67, 3269-3275.	0.4	18
220	Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. <i>Blood</i> , 2007, 109, 4698-4707.	0.6	171
221	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 497-499.	2.0	5
222	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2007, 92, 418-420.	1.7	15
223	Current role of allogeneic stem cell transplantation in follicular lymphoma. <i>Haematologica</i> , 2007, 92, 580-582.	1.7	1
224	Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. <i>Haematologica</i> , 2007, 92, 1513-1518.	1.7	34
225	Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. <i>Leukemia</i> , 2007, 21, 12-17.	3.3	349
226	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007, 21, 1802-1811.	3.3	66
227	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007, 21, 2316-2323.	3.3	142
228	Unrelated donor hematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 330-337.	1.1	25
229	Molecular Methods Used for The Detection of Autologous Graft Contamination in Lymphoid Disorders. <i>Methods in Molecular Medicine</i> , 2007, 134, 179-196.	0.8	1
230	Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Blood</i> , 2006, 107, 3415-3416.	0.6	75
231	Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. <i>Bone Marrow Transplantation</i> , 2006, 37, 311-315.	1.3	2
232	Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006, 37, 1135-1141.	1.3	98
233	Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. <i>Leukemia</i> , 2006, 20, 329-335.	3.3	42
234	Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. <i>Leukemia</i> , 2006, 20, 1533-1538.	3.3	235

#	ARTICLE	IF	CITATIONS
235	Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. <i>Leukemia</i> , 2006, 20, 1840-1847.	3.3	18
236	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. <i>Experimental Hematology</i> , 2006, 34, 721-727.	0.2	25
237	Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Tj ETQq1 106784314 rgBT/O		
238	Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3158-3158.	0.6	1
239	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2006, 91, 837-9.	1.7	38
240	Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2005, 35, 121-124.	1.3	21
241	The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. <i>Bone Marrow Transplantation</i> , 2005, 35, 609-617.	1.3	59
242	Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. <i>Leukemia</i> , 2005, 19, 1029-1033.	3.3	149
243	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. <i>Experimental Hematology</i> , 2005, 33, 920-927.	0.2	40
244	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. <i>Cancer</i> , 2005, 104, 2099-2103.	2.0	50
245	Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5334-5346.	0.8	125
246	Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 6690-6698.	0.8	58
247	Role of stem cell transplantation in myeloma. <i>Hematology</i> , 2005, 10, 127-128.	0.7	2
248	Immune-mediated attack in relapsed Hodgkin's lymphoma. <i>Lancet, The</i> , 2005, 365, 1906-1908.	6.3	14
249	Molecular Modeling of Stereo- and Regioselectivity of Group 4 Heterocenes in the Polymerization of Propene. <i>Macromolecules</i> , 2005, 38, 3973-3976.	2.2	14
250	Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells. <i>Journal of Clinical Oncology</i> , 2004, 22, 2172-2176.	0.8	301
251	Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes. <i>Journal of Clinical Oncology</i> , 2004, 22, 1460-1468.	0.8	116
252	Do New Century Catalysts Unravel the Mechanism of Stereocontrol of Old Ziegler-Natta Catalysts?. <i>Accounts of Chemical Research</i> , 2004, 37, 231-241.	7.6	232

#	ARTICLE	IF	CITATIONS
253	Do New Century Catalysts Unravel the Mechanism of Stereocontrol of Old Zieglerâ€™Natta Catalysts?. <i>ChemInform</i> , 2004, 35, no.	0.1	0
254	Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. <i>Blood</i> , 2004, 103, 3287-3295.	0.6	47
255	Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.. <i>Blood</i> , 2004, 104, 808-808.	0.6	5
256	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004, 89, 717-41.	1.7	48
257	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. <i>Experimental Hematology</i> , 2003, 31, 784-788.	0.2	13
258	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2003, 31, 767-773.	1.3	15
259	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 791-793.	1.3	10
260	Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. <i>Leukemia</i> , 2003, 17, 841-848.	3.3	180
261	PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 1398-1403.	0.8	35
262	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003, 102, 749-755.	0.6	193
263	Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. <i>Blood</i> , 2003, 102, 1927-1929.	0.6	176
264	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood</i> , 2002, 99, 75-82.	0.6	147
265	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. <i>Blood</i> , 2002, 99, 4234-4236.	0.6	209
266	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2002, 100, 1559-1565.	0.6	89
267	Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. <i>Blood</i> , 2002, 99, 390-391.	0.6	10
268	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. <i>British Journal of Haematology</i> , 2002, 117, 642-645.	1.2	11
269	Central Nervous System Relapse in a Patient with Mantle Cell Lymphoma in Continuous Clinical and Molecular Remission at Six Years Since Autografting. <i>Leukemia and Lymphoma</i> , 2001, 40, 679-682.	0.6	6
270	Maspin and mamaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. <i>Annals of Oncology</i> , 2001, 12, 1693-1698.	0.6	55

#	ARTICLE	IF	CITATIONS
271	High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. <i>Leukemia</i> , 2001, 15, 256-263.	3.3	28
272	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001, 15, 1941-1949.	3.3	49
273	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. <i>Experimental Hematology</i> , 2001, 29, 183-193.	0.2	64
274	P1. Immunoablation with t cell depleted autologous peripheral blood stem cell rescue produces complete remission in thrombocytopenic purpura (TTP) recidivant and refractory to standard treatment. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 708-716.	0.5	0
275	What Do the People Think (and Know) About Informed Consent for Participation in a Medical Trial. <i>Archives of Internal Medicine</i> , 2001, 161, 768-769.	4.3	9
276	Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. <i>Bone Marrow Transplantation</i> , 2000, 26, 1185-1191.	1.3	59
277	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. <i>Leukemia</i> , 2000, 14, 740-747.	3.3	35
278	Geometry and Stability of Titanium Chloride Species Adsorbed on the (100) and (110) Cuts of the MgCl ₂ Support of the Heterogeneous Ziegler-Natta Catalysts. <i>Macromolecules</i> , 2000, 33, 8953-8962.	2.2	127
279	Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells. <i>Journal of Clinical Oncology</i> , 1999, 17, 208-208.	0.8	222
280	Hemopoietic Progenitor Cell Mobilization and Harvest Following an Intensive Chemotherapy Debulking in Indolent Lymphoma Patients. <i>Stem Cells</i> , 1999, 17, 55-61.	1.4	26
281	Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. <i>Leukemia</i> , 1999, 13, 1456-1462.	3.3	37
282	Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies. <i>Leukemia</i> , 1999, 13, 1691-1695.	3.3	42
283	G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. <i>Bone Marrow Transplantation</i> , 1998, 21, 401-407.	1.3	55
284	Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 449-455.	1.3	48
285	Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. <i>Nature Genetics</i> , 1997, 17, 226-230.	9.4	322
286	Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. <i>Blood</i> , 1997, 89, 724-491.	0.6	158
287	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. <i>Leukemia</i> , 1997, 11, 1793-1798.	3.3	99
288	Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. <i>Bone Marrow Transplantation</i> , 1997, 20, 341-343.	1.3	7

#	ARTICLE	IF	CITATIONS
289	Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. <i>British Journal of Haematology</i> , 1997, 99, 41-46.	1.2	15
290	Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. <i>British Journal of Haematology</i> , 1997, 99, 685-691.	1.2	16
291	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. <i>Blood</i> , 1996, 88, 2228-2235.	0.6	197
292	Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. <i>British Journal of Haematology</i> , 1996, 94, 376-378.	1.2	28
293	Oncogenes in the Pathogenesis of Multiple Myeloma. , 1996, , 169-172.		0
294	Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system. <i>Bone Marrow Transplantation</i> , 1996, 18, 1117-21.	1.3	20
295	High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. <i>Blood</i> , 1995, 85, 1596-1602.	0.6	133
296	Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma.. <i>EMBO Journal</i> , 1995, 14, 6209-6217.	3.5	243
297	Haematological support of high-dose sequential chemotherapy: Clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. <i>Annals of Oncology</i> , 1995, 6, S3-S8.	0.6	17
298	Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. <i>Blood</i> , 1994, 83, 1757-1759.	0.6	295
299	N- and K-Ras Oncogenes in Plasma Cell Dyscrasias. <i>Leukemia and Lymphoma</i> , 1994, 15, 17-20.	0.6	28
300	Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. <i>Blood</i> , 1994, 83, 1757-1759.	0.6	76
301	Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. <i>Leukemia</i> , 1994, 8, 758-67.	3.3	82
302	THE MUTATION OF N-RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA. <i>British Journal of Haematology</i> , 1993, 83, 672-673.	1.2	3
303	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-2713.	0.6	116
304	Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.. <i>Journal of Experimental Medicine</i> , 1993, 178, 1091-1096.	4.2	109
305	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-2713.	0.6	2
306	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-13.	0.6	31

#	ARTICLE	IF	CITATIONS
307	B cell lymphoma-associated chromosomal translocation involves candidate oncogene <i>lyt-10</i> , homologous to NF- κ B p50. <i>Cell</i> , 1991, 67, 1075-1087.	13.5	430
308	Dual rearrangement of immunoglobulin and T cell receptor gene in a case of T cell hairy cell leukemia. <i>European Journal of Haematology</i> , 1991, 46, 71-76.	1.1	6
309	Human homologue of Moloney leukemia virus integration-4 locus (MLV-4), located 20 kilobases 3' of the <i>myc</i> gene, is rearranged in multiple myelomas. <i>Cancer Research</i> , 1990, 50, 6478-82.	0.4	25
310	Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. <i>Cancer Genetics and Cytogenetics</i> , 1989, 39, 77-80.	1.0	3
311	Free Calcium Concentration in Platelets of Patients with Essential Hypertension. <i>American Journal of Nephrology</i> , 1986, 6, 54-56.	1.4	3
312	New model of the origin of the stereospecificity in the synthesis of syndiotactic polypropylene. <i>Macromolecules</i> , 1985, 18, 2030-2034.	2.2	37
313	Analysis of models for the Ziegler-Natta stereospecific polymerization on the basis of non-bonded interactions at the catalytic site. I. The Cossee model. <i>European Polymer Journal</i> , 1979, 15, 1133-1141.	2.6	127
314	Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 0, , .	2.5	1